Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Dacomitinib for Metastatic NSCLC

Sep 28, 2018, 10:49 AM
URL:
On September 27, the Food and Drug Administration approved dacomitinib tablets (Vizimpro, Pfizer Inc.) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Read the full FDA press release here.

Posted 9/28/18

Leave a comment